

Title:

Atrial Fibrillation Screening in High-Risk Patients Using a Single Lead ECG Device: A Tertiary Hospital Experience

Authors:

1. Tesfamariam Betemariam Aklilu

Affiliation: Addis Ababa University

Email: Tesfamariam112@gmail.com

2. Meskerem Aleka Kebede

Affiliation: London School of Economics and Political Science

Email: m.kebede@lse.ac.uk

3. Duffera Mekonnen

Affiliation: Addis Ababa University

Email: senyiduf@yahoo.com

4. Yidnekachew Birhan Asrat

Affiliation: Addis Ababa University

Email: yidnekasrat1@gmail.com

5. Adane Sikamo Petros

Affiliation: Addis Ababa University

Email: adane.petros@aau.edu.et

6. Desalew Mekonnen

Affiliation: Addis Ababa University

Email: desalewm@yahoo.com

Address for Correspondence:

Tesfamariam Betemariam Aklilu

Affiliation: Addis Ababa University

Email: Tesfamariam112@gmail.com

Address: Addis Ababa, Ethiopia

ABBREVIATIONS AND ACRONYMS

AAU: Addis Ababa University

AF: Atrial Fibrillation

CHS: College of Health science

ECG: Electrocardiography

ESC: European society of cardiology

ETB: Ethiopian Birr

GFR: Glomerular Filtration Rate

IHD: Ischemic Heart Disease

LDL: Low-density lipoproteins

NICE: National Institute for Health and Care Excellence

OAC: Oral Anticoagulation

SL: Single Lead

TASH: Tikur Anbessa Specialized Hospital

WB: World Bank

WHO: World Health Organization

Table of contents

Table of Contents

ABBREVIATIONS AND ACRONYMS	2
Table of contents	3
Abstract	6
1. Introduction	7
1.1. Background	7
1.2 Statement of The Problem	8
1.3 Significance of The Study	8
2. Literature Review	8
2.1 Introduction	8
2.1 Prevalence of AF	8
2.3 Complications of AF	9
2.4 AF Screening	9
3. OBJECTIVE	10
3.1 General Objective	10
3.2 Specific Objectives	10
4. METHODOLOGY	10
4.1. Study Setting	10
4.1.1. Study Area.....	10
4.1.2. Study Period	11
4.2. Study Design	11
4.3. Source and Study population	11
4.4. Eligibility Criteria	11
4.4.1. Inclusion Criteria.....	11
4.4.2. Exclusion Criteria	11
4.5 Sample size Determination and Sampling Technique	11
4.6. Study Variables	12
4.6.1. Outcome Variable	12
4.6.2. Explanatory Variables.....	12

4.7. Operational Definitions	13
4.8. Data Collection Procedures	13
4.8.1. Data Collection Instruments	13
4.8.2. Data quality and management	14
4.8.3 Data Analysis	15
4.9. Ethical consideration	15
4.10. Dissemination of the results	15
5.Results.....	16
5.1 Descriptive Analysis	16
5.1.1 Sociodemographic characteristics	16
5.1.2 Clinical characteristics of patients.....	16
5.2 Prevalence of AF	18
5.3 Ability to detect newly diagnosed AF by screening and PPV of SL-ECG.....	18
5.4 Factors Associated With AF	19
5.4 Stroke Risk Stratification.....	20
6. Discussion.....	20
7. Recommendations, Conclusion	22
8. Limitation of The Study.....	22
9. References.....	23

List of Tables and Figures

Table 1 Sample size calculation	12
Table 2 Study Variables.....	13
Table 3 Comparison of baseline characteristics	17
Table 4 Bivariate logistic regression analysis of selected variables	19
Table 5 Multivariate regression output of selected variables	20
Figure 1 Comparison of AF detection among age groups.....	18
Figure 2 ROC curve.....	22
Figure 3 Treatment characteristics in patients with AF	20

Abstract

Background: Atrial Fibrillation (AF) is a major public health problem and one of the commonest supraventricular arrhythmias. At least 20% of all strokes are directly attributable to AF. However, its burden is not clear in sub-Saharan Africa, possibly due in part to undervaluation and non-recognition. In recent decades several new devices have been developed for the betterment of the accuracy and rates of AF detection, which also offers flexibility and feasibility.

Objective: The objective of the study is to identify the prevalence of known and Unknown AF in a high-risk patient population using a validated single-lead ECG.

Methods and materials: An institution-based cross-sectional study was conducted in 410 adults (≥ 55 years) recruited from Tikur Anbessa hospital sub-specialty outpatient clinics from July to October 2021. ECG tracing was conducted using (AliveCor) SL ECG device. A standardized questionnaire was designed to collect socio-demographic and clinical information using ODK Collect v2021. 3.0. we used logistic regression to determine the potential associated factors.

Results: The overall prevalence of AF in our study was 4.8%. It was strongly associated with age, diagnosis of heart failure, Substance use and high monthly income according to World Bank (WB) category. All the newly diagnosed patients were not on anticoagulation for stroke prevention.

Conclusion and Recommendations: Single timepoint screening in high-risk patients identified previously unknown AF in 2.1 %, out of which the majority were eligible for anticoagulation therapy. Identification of AF through targeted screening with up incoming novel technologies could reduce the stroke burden associated with undiagnosed AF.

Key words: Atrial Fibrillation, single lead ECG, Screening, high risk

1. Introduction

1.1. Background

Atrial Fibrillation (AF) is a major public health problem and one of the commonest supraventricular arrhythmias.¹ Early identification of atrial fibrillation (AF) is emerging as a priority in cardiology practice because of its association with substantial morbidity and mortality. AF increases cardiovascular disease risk, resulting in a five-fold increased stroke risk.^{2,3} At least 20% of all strokes are directly related to AF, and in 20-45% of cases AF is first diagnosed at the time of stroke⁴. This value is likely an underestimate because a sizable proportion of cryptogenic stroke is due to undetected AF.^{5,6} Patients with AF don't only have a high risk of overt stroke they are also at an increased risk of a silent vascular brain lesion. Evidently, both Alzheimer's and Vascular dementia were diagnosed in participants with no history of a clinical stroke and after accounting for possible stroke risk factors in a recent Korean study.^{7,8}

Atrial fibrillation (AF) is an epidemic with significant health and economic impact. In 2010, there were around 33 million people worldwide estimated to have AF and this value is expected to double by 2050.⁹ Its burden is not clear in sub-Saharan Africa, possibly due in part to under valuation and non-recognition.^{10,11} There are only a hand full of population screening studies for AF across the African continent, and these studies have reported relatively low AF burden, together with a very significant heart failure and stroke burden. This shows more robust evidence from large scale screening studies is not yet available.¹²

Commonly used AF screening strategies are opportunistic or systematic screening of individuals with risk factors particularly people, above the age of >_65 years or with other risk factors suggestive of increased stroke risk. These groups are usually screened by single-point or repeated 30-s ECG recording over a period of 2 weeks. Multiple new devices have been developed to improve the accuracy and rates of AF detection, which also offer flexibility and feasibility.¹³ One such device is the AliveCor SL ECG device. However, limited data exist on their use for AF screening in low-resource countries even though it is approved by the US Food and Drug Administration (FDA) for automatic classification of 30-second single-lead ECG tracing as normal or possible AF.¹⁴

“An ounce of prevention is worth a pound of cure” a famous quote by Benjamin Franklin emphasizing the need for screening. The World Health Organization lists different conditions that should be fulfilled to justify mass screening.¹⁵ AF meets all these criteria. Screening for malignancies conditions is recommended even though the findings might not impact the patients' life expectancy, but in the case of AF screening has an instantaneous indication for OAC treatment in those individuals with high CHA2DS2-VASC score.

Therefore, the aim of this study is to determine the overall prevalence of known and new AF, identifiable by single time-point screening using single lead ECG, examine their CHA2DS2-VASC score and eligibility for OAC in those with previously missed AF and introduce the use SL ECG device in low resource setup.

1.2 Statement of The Problem

Atrial fibrillation has become a major public health issue of epidemic proportion. Although many patients with AF present with palpitations, there is likelihood that their initial manifestation might be a debilitating stroke or death. Diagnosing AF before symptoms manifest could lead to initiation of appropriate effective therapy. Data in the prevalence of AF are scarce in the sub-Saharan African population. Utilization of newer smart ECG devices could be an effective mechanism to assess prevalence and explore the applicability of the devices to cardiology practice in Ethiopia.

1.3 Significance of The Study

This study will provide data on the prevalence of AF in asymptomatic patients and identify a missed opportunity. Since early and timely detection of AF will help prevent stroke

2. Literature Review

2.1 Introduction

AF is characterized as an irregular, disorganized and rapid atrial activation with loss of atrial contraction causing an irregular ventricular rate. This response is determined by AV nodal conduction. Atrial Fibrillation (AF) is a significant public health problem and one of the commonest supraventricular arrhythmias.¹

2.1 Prevalence of AF

Atrial Fibrillation burden has been on the rise since the 1990s with a doubling of cases in the last 3 decades,¹⁶ Current world prevalence is about 1–3% in the general population but increases with increasing age (from 9% in those above the age of 65 to 17% in those above 80 years old), presence of co morbidities, male sex, ethnicity, region, and screening method used.^{17–21} According to the Global Burden of Disease study in 2010, the prevalence of AF (age-adjusted, per 100 000 population) was 659.8 (95% UI, 511.0–850.4) for men and 438.1 (95% UI, 340.2–561.0) for women in Sub Saharan Africa.¹⁹ However, the GBD study also pointed out the scarcity of data in Sub-Saharan Africa and recommended targeted population studies for a better estimate.²³ In addition this part of the world is undergoing a major epidemiological transition with adoption of western lifestyle and suffering the consequences that come with it. These are hypertension, dyslipidemia, diabetes, and obesity all risk factors for cardiovascular diseases. There is an even larger deficiency of evidence in Ethiopia. A study done in TikurAnbesa Specialized Hospital (TASH) reveals prevalence of AF in RHD was (46.8%), a high prevalence of cardio embolic event (9.2%).²⁴ Another Ethiopian study evaluating the overall prevalence of AF in a community-based cross-sectional study community done in Jimma town was alarmingly high at 4.3% compared to the 0.5% from the GBD 2010 study.²⁵ To our knowledge this previous study

is the only community survey done in the country. We couldn't find any data on the prevalence of non-rheumatic AF in the Ethiopian context.

2.3 Complications of AF

Many patients with AF manifest symptoms leading to detection of the arrhythmia and appropriate management. However, a significant number of patients can present with debilitating stroke more so than ischemic stroke secondary to arterial disease.²⁶ Detecting asymptomatic AF could enable the initiation of appropriate therapy, including oral anticoagulants (OACs) and prevent stroke and related complications. The other benefit is potential initiation of risk-factor modifiers.^{13,18,27} Oral anticoagulation is estimated to reduce stroke risk for people with AF by about 65% compared to placebo,^{3,28} but the real-world evidence on the use of anticoagulation in deserving patients is low in one study in Europe only 29.5% were receiving oral anticoagulants.²²

2.4 AF Screening

Currently opportunistic pulse palpation together with 12 lead ECG screening is practiced as a strategy to increase timely AF detection rate in high-risk patients. This is mainly based on the 60% improvement in AF detection in the landmark SAFE trial.²⁹ Based on this the European society of cardiology (ESC) recommends opportunistic screening for those above the age of 65. Citing the above evidence, the National Institute for Health and Care Excellence (NICE) also recommends screening but has a more stringent criteria where screening is recommended for patients with symptoms suggestive of AF.^{13,30}

However, some international recommendations against screening exist. These are underpinned by three major explanations. First, the cost implications and uncertainty over the benefits of a systematic screening program compared to usual care³¹ like the US Preventive Services Task Force citing a metaanalysis which 1-time systematic screening with ECG did not detect more cases than opportunistic screening with pulse palpation.³² Second argument is based on the potential harms of screening with ECG like misinterpretation of ECGs strips by primary care physicians, resulting in unnecessary treatments for individuals without atrial fibrillation.³³ Third, argument made by authors is that under treatment of known atrial fibrillation has to be prioritized. This is based on evidence that indicate low rate of appropriate therapy in such patients. For instance, a Swedish study revealed that only 57% of patients were on OAC even though they already had an established AF diagnosis.⁹

Multiple new devices have been developed to improve the accuracy and rates of AF detection. These new technologies produce rapid results and are deemed to be cost effective compared to prior methods like pulse checking and 12-lead ECG for AF screening.^{34,35}

Different studies and systematic reviews using one single ECG recording found new AF in 1.4% of subjects >65 years which is high enough to support the use of single time-point Screening.³⁶ Interestingly the stroke stop study found 0.5% new AF via the initial ECG recording but with intermittent systematic screening detection of new AF increased 4-fold to 3% of the screened population.³⁷ This shows us that most paroxysmal AF can be missed using single time ECG.

Which strengthens the argument for screening. While many devices have been developed for the detection of AF, the most appropriate approach to deploy depends on various factors such as underlying AF, stroke risk, convenience, and cost.³⁸

In general, experts have reviewed major knowledge gaps and identified critical research priorities one of which is role of opportunistic screening in AF.²⁴ As mentioned previously, the therapeutic and prognostic implications of screening AF are still debatable. Moreover, uniform consensus does not exist whether one approach is superior to the other. Therefore, during the National Heart, Lung, and Blood Institute's virtual workshop which convened to identify key research priorities in the field flagged AF screening as one of the most important research priorities in 2021.³⁹

3. OBJECTIVE

3.1 General Objective

The objective of the study is to determine the prevalence of AF in a high-risk patient population using a validated single lead ECG

3.2 Specific Objectives

- To assess baseline characteristics of high-risk patients presenting to the OPD.
- Prevalence of known and unknown AF in high-risk patients attending outpatient clinics
- To assess the association between the CHA₂DS₂-VASc score and associated values with the occurrence of AF
- Examine thromboembolism risk and eligibility for treatment in those with previously undiagnosed AF

4. METHODOLOGY

4.1. Study Setting

4.1.1. Study Area

The study was conducted at TASH, the biggest tertiary health care center in Addis Ababa Ethiopia. The hospital provides specialized medical care to patients across the country who are referred for various specialty care programmes. The hospital also serves as the main medical training center for undergraduate, specialty training and fellowship trainings. The cardiac clinic caters close to 1500 patients per month, the outpatient service provides Echocardiography and 12 lead ECG services as well. All new cardiovascular patients are evaluated by a cardiologist.

4.1.2. Study Period

The study was conducted in Addis Ababa Tikur Anbessa hospital (TASH) Cardiac sub-specialty outpatient clinics from July to October 2021.

4.2. Study Design

An institution based cross sectional study was conducted to achieve the aims of this study.

4.3. Source and Study population

All patients attending internal medicine cardiac, renal, and diabetic specialty clinics for the follow up of different illnesses during the study period.

4.4. Eligibility Criteria

4.4.1. Inclusion Criteria

All adult patients above the age of 55 attending selected internal medicine (Diabetes, Renal and cardiac) specialty clinics were included.

4.4.2. Exclusion Criteria

Patients who had an established diagnosis of Rheumatic heart disease and those that refused to give informed consent were excluded.

4.5 Sample size Determination and Sampling Technique

Formula for single population Proportion

$$n \geq \frac{(Z_{\alpha/2})^2 \cdot P(1-p)}{d^2}$$

Where, p= Expected population proportion of the event: 4.3%

$$Q = 1-p$$

d= degree of absolute precision/ error tolerated (0.02)

Z $\alpha/2$ = Standard normal variable at 95% Confidence level (1.96)

A sample of 395 was calculated using a single population proportion formula assuming AF prevalence of 4.3 based on the Jimma community based cross sectional study 95% confidence level, 2 % margin of error.²⁵

Table 1 Sample size calculation

Objective	Formula	Assumption	Sample size
Screening of AF in high-risk patients attending outpatient clinics	$n \geq ((Z\alpha/2)^2 * P(1-p)) / d^2$	P: 4.3% D: 0.02 95% Confidence level (1.96)	395
Prevalence of AF in high-risk patients attending outpatient clinics	$n \geq ((Z\alpha/2)^2 * P(1-p)) / d^2$	P: 7.2% D: 0.03 95% Confidence level (1.96) P was taken from a UK study	285
To assess the association between the CHADS2VAS score and associated values with the occurrence of AF	$n \geq ((Z\alpha/2)^2 * P(1-p)) / d^2$	P: 20% D: 0.05 95% Confidence level (1.96) P was taken from the Rotterdam study ⁽⁴⁰⁾	245
Examine thromboembolism risk and eligibility for treatment in those with previously undiagnosed high-risk patients with AF	$n \geq ((Z\alpha/2)^2 * P(1-p)) / d^2$	P: 30% D: 0.05 95% Confidence level (1.96) P was taken from the Framingham study ⁴¹	322

Simple random sampling was used to determine participation in the study.

4.6. Study Variables

4.6.1. Outcome Variable

For this study the main dependent variable was the detection of AF

4.6.2. Explanatory Variables

Independent/Explanatory Variables were selected based on extensive literature review and evidence-based assumption concerning their potential impact on AF.

Table 2 Study Variables

Patient Socio-Demographic Characteristics
Age Gender Income category (based on WB category) Level of education Marital status Ethnicity
Anthropometric Measurements
BMI
Clinical and Laboratory Characteristics
Diagnosis of Diabetes Diagnosis of Hypertension Diagnosis of Heart Failure Diagnosis of Anemia Diagnosis of COPD Diagnosis of IHD LDL Estimated GFR
Behavioral Factors
Smocking Status Alcohol consumption Khat Chewing
Treatment Characteristics
Oral Anticoagulation use Aspirin Use

4.7. Operational Definitions

Definite diagnosis of AF in screen-positive cases is established only after the physician reviews the single-lead ECG recording of >_30 s or 12-lead ECG and confirms that it shows AF.

4.8. Data Collection Procedures

4.8.1. Data Collection Instruments

Clinical and laboratory profiles of participants were obtained by reviewing digital records of patients using data extraction tool. Structure questionnaire was prepared to collect socio demographic data from patients using the WHO STEPS Instrument for Chronic Disease Risk Factor Surveillance.⁴² The questionnaire was prepared in English and translated into Amharic and

re-translated back to check its consistency ([appendix VI](#)). A pretest was conducted before the actual data collection begun.

Patients underwent AF screening using the AliveCor Heart Monitor¹. This SL-ECG consists of a pair of electrodes and produces results corresponding to the lead I in the 12-lead ECG.⁴³ For all patient's fingers of each hand are placed on each electrode and the ECG recorded for about 30 seconds which instantly transmits tracings to a device with the KardiaMobile Application. We used a Samsung device (version 5.18.2) that produces automated reports of ECG readings as 'Normal', 'AF', or 'Unclassified'. A 12-lead ECG was performed for the subjects identified as having AF on the SL ECG device, and all 12-lead ECGs were reviewed by the first author of this manuscript.




Figure 1: Patient undergoing SL ECG examination

Participant's anthropometry was assessed during the study. Weight was taken using standard beam balance and scale. Height was measured using standard measuring scale

Data was collected using ODK Collect v2021. 3.0 and stored on the Kobo Toolbox server. Four medical interns were recruited and given adequate familiarization training before the commencement of data collection.

4.8.2. Data quality and management

The data was checked for completeness and consistency at the end of each data collection day and continuous supervision and monitoring took place during the whole duration. The data was explored and cleaned. We assumed missingness of values to be completely at random (CRD) and hence we opted for complete case detection. Data cleaning processes were validated with the data collectors to confirm accuracy. Outliers were assessed and counter checked with patient files to double check entry and considered. String variables were uniformized to facilitate analysis.

¹ AliveCor SL ECG device is [Cleared by the United States Food and Drug Administration](#), CE marked and clinically validated.

Some continuous variables (Age, BMI, estimated GFR) were categorized according to universally accepted definitions. Prior to bivariate analysis, relevant categorical variables are restructured to produce results easily adaptable to clinical settings.

4.8.3 Data Analysis

Data was analyzed using Stata version 16.1 (StataCorp LP, College Station, TX, USA). Test statistics with p-values <0.05 were considered significant and CIs were calculated for a 95% level of confidence.

The distribution of each relevant variable was explored using graphical methods, where uncertainty exists this was substantiated by the D'Agostino's K^2 test. Essential sociodemographic and clinical characteristics were presented using standard descriptive statistics (counts, proportions, means, standard deviations (SD), medians, interquartile ranges (IQR)).

A bivariate analysis was performed to analyze associations between AF and potential predictor variables appropriate test statistics were used where relevant (see [Appendix IV](#)). A multivariable logistic regression was conducted to evaluate the compounded effects of associated factors and adjust for confounders. Potential independent variables were identified a priori from published literature. Model diagnostic tests were conducted to ensure the fitted logistic regression estimated the outcome to a reasonable extent. Hence, Hosmer-Lemeshow-Test (HLT) and post model ROC (Receiving Operating Characteristic) curve was plotted.

4.9. Ethical consideration

Ethical clearance was obtained from the AAU college of health sciences Internal Medicine Department Ethical Review Board. The safety and privacy of subjects was protected by anonymizing identified information during data collection and analysis. Informed written consent was obtained from participants of the study ([Appendix II](#)).

4.10. Dissemination of the results

The final output of this study will be submitted to Addis Ababa University, College of health sciences. It will be presented at different seminars, journals, and workshops. Finally, efforts will be made to publish in peer-reviewed journals.

5.Results

5.1 Descriptive Analysis

5.1.1 Sociodemographic characteristics

A total of 410 patients attending three internal medicine specialty clinics (Diabetes, Renal and Cardiac) took part in screening. 15 patients were excluded from the dataset because of previous history of valvular heart disease and incomplete history of comorbidities. A total of 395 patients were included in the final analysis of the study. The comparison of baseline characteristics of the patients is presented in the (table 3) below. More than half of the study participants were female (n=207, (52.42%)). The median age is 65.00 (IQR 58.00-72.00) and most of the participants are under the age of 65. (N=236 (59.75%)). More than half of the participants (48.1%) were from Oromia, (30.13%) from Amhara and about 13% from SNNPR with a small fraction from other regions in Ethiopia.

Out of all participants, 308 (77.97%) were married and 44 (11.14%) were widowed the remaining ones were either single or divorced. Most participants have completed primary Education 179(42.32%) and have average income per month (n=106, 26.84%) based on the world bank's classification. Occupation wise majority of our participants were housewife and employed by the government. (n=110, 27,85% and 70, 17.72% respectively).

5.1.2 Clinical characteristics of patients

The most frequent diagnosis among participants was Type 2 DM (n=229, 57.97%), followed by hypertension (n=218, 55.19%) and Heart failure (n=80 ,20.25%). All patients with heart failure have an echocardiography result showing the cause is not a valvular heart disease. Concerning anthropometric indices, the mean BMI was (24.93 +- 3.85), with more than half of the participants (55.44%) being either overweight (n=159, 40.25) or obese (n=60, 15.19%). Only about 169 (42.78%) of our participants had their Lipid profile checked (Registered) in the past 6 months. For those that had registered the median LDL value was 105 (83-126). Complete clinical characteristics of patients and the comparison of values in those with and without Atrial Fibrillation is presented in table 3 below.

Table 3 Comparison of baseline characteristics

Variable	New AF (N=8)	Known AF (N=11)	No AF (N=376)
Sex			
Male, n (%)	5 (62.50)	5(45.45)	178(47.34)
Female	3(37.50)	6(54.55)	198(52.66)
Age Categories(years), n(%)			
55-65	3(37.50)	4(36.36)	230(61.17)
65-75	1(12.50)	7(63.64)	99(26.33)
>75	4(50.00)	0(0)	47(12.50)
Marital Status, n (%)			
Single	1(12.50)	0(0)	28(7.45)
Married	6(75.00)	11(100)	29(77.39)
Divorced	0	0	14(3.72)
Widowed	1(12.50)	0	43(11.44)
Ethnicity, n (%)			
Amhara	3(37.50)	4(36.36)	112(29.79)
Gumuz	0	0	1(0.27)
Oromo	4(50.00)	4(36.36)	182(48.4)
SNNPR	0	3(27.27)	50(13.30)
Sidama	0	0	4(1.06)
Somalia	0	0	1(0.27)
Tigray	1(12.5)	0	26(6.91)
Occupation, n (%)			
Housewife	1(12.50)	3(27.27)	106(28.19)
Farmer	2(25.00)	2(18.18)	21(5.59)
Civil Servant	2(25.00)	1(9.09)	67(17.82)
Merchant	0(0)	1(9.09)	18(4.79)
Others	3(37.50)	4(36.36)	164(43.62)
Income Status n, (%)			
Low Income	7(87.50)	6(54.55)	259(68.88)
Average Income	0	3(27.27)	103(27.39)
High Income	1(12.50)	2(18.18)	14(3.72)
Education n, (%)			
Primary Education	4(50.00)	5(45.45)	169(44.95)
Secondary Education	3(37.50)	3(27.27)	95(25.27)
Higher Education	1(12.50)	3(27.27)	112(29.79)
BMI (kg/m²) categorized, n (%)			
<18.5	0(0)	0(0)	14(3.72)
18.5-24.9	4(50)	5(45.45)	153(40.69)
25.0-29.9	4(50)	5(45.45)	150(39.89)
>30	0	1(9.09)	59(15.69)
Pulse Rate(bpm), mean			
	109.25(+/-33.59)	105.90(+/-37.11)	86.71(+/-86.71)
Estimated GFR², categorized, n (%)			
Group 1 (Normal > 90)	5(62.50)	7(63.64)	317(84.31)
Group 1 (eGFR 60-90)	2(25.00)	3(27.27)	31(8.24)
Group 2 (eGFR 30-60)	1(12.50)	1(9.09)	18(4.79)
Group 3 (eGFR 29-30)	-	-	9(2.39)
Group4 (eGFR <15)	-	-	1(0.27)
Medical History, n (%)			
Diabetes	2(25.00)	10(90.91)	217(57.71)
IHD	2(25.00)	1(9.09)	27(7.23)
Heart failure	1(12.50)	6(54.55)	73(19.41)
Asthma	0(0)	1(9.09)	21(5.59)
COPD	0(0)	0(0)	3(0.80)
Anemia	1(12.50)	1(9.09)	23(6.12)
CKD	2(21.05)	2(18.18)	57(15.16)
Hypertension	3(37.50)	9(81.82)	206(54.79)
Hyperthyroidism	0(0)	0(0)	19(5.05)
CHA₂DS₂-VAsc n (%)			
Score <2	1(12.5)	1(9.09)	81(21.54)
Score ≥ 2	7(87.5)	10(90.91)	295(78.46)
Substance Use n (%)			
Alcohol	3(37.50)	1(9.09)	31(8.24)
Smoking	2(25.00)	0(0)	13(3.46)
Chat Chewing	0(0)	0(0)	18(4.79)

² GFR is estimated and categorized using the recommendations by [CKD-EPI equation](#).

Variable	New AF (N=8)	Known AF (N=11)	No AF (N=376)
LDL (mg/dl), n(%)			
LDL < 100	3(37.5)	3(27.27)	
LDL ≥ 100	5(62.5)	8(72.73)	
Treatment n, (%)			
Aspirin	0(0)	2(18.18)	117
Warfarin	0(0)	9(81.82)	16

5.2 Prevalence of AF

Of the initial single-lead ECG tracings obtained from 395 participants, the KardiaMobile algorithm was able to provide a rhythm decision in 86% (340/395) of screened patients the rest of the outputs indicated unclassified (19/395, 4.81%), unreadable (36/395, 9.11%) recordings. Samples of ECG Kardia output are presented in the appendix ([appendix VI](#)). A repeat tracing was obtained in 49 (89%) of the participants who did not have an initial rhythm decision. Of those participants without repeat KardiaMobile tracings, 100% (19/55) had an initial result of unclassified, which the screening team deemed as sinus tachycardia (>100 bpm) and interpreted as normal rhythm not requiring a repeat tracing,

AF was detected in 22 patients (5.57%) using the single lead ECG. Manual confirmation of the tracings indicated that 3 of the patients were erroneously classified AF by automated reading and when a confirmatory 12 Lead ECG was obtained these patients turned out to have sinus arrhythmia, RBBB and sinus rhythm. All the 22 patients received 12 lead ECG to confirm the diagnosis of AF. Out of these A previous diagnosis of Non valvular AF was present in 11 patients (2.78%, the majority of whom were men (n=10, 52.63%)). The overall prevalence of New AF detected by SL-ECG or known AF was 4.81% (19/395) with similarly a higher prevalence in men (n=10, 52.63%) than women.




Figure 2 Comparison of AF detection among age groups

5.3 Ability to detect newly diagnosed AF by screening and PPV of SL-ECG

Of the AF detected from 395 participants, new AF was detected in 8 patients (2.03%), known AF was detected in 11 patients. In total the prevalence of AF was determined to be 4.8% in the study population. There was a 42.1% (8/19) increase in the prevalence rate of AF with this screening programme. The PPV of the SL ECG calculated in our study is 86.3%.

Table 4 Bivariate logistic regression analysis of selected variables

Variable	COR (95% CI)	P-value
Sex		
Male	1.24(0.49-3.11)	0.653
Age		
55-65	Reference	
65-75	2.66(0.93-7.52)	0.06
>75	2.80(0.79-9.94)	0.11
Marital Status		
Divorced	Reference	
Married	2.51 (0.33 - 19.36)	0.38
Single	1.54 (.092-25.57)	0.77
BMI (kg/m²)		
<18.5	(No value)	
18.5-24.9	Reference	
25-29.9	1.02(0.39-2.64)	0.96
>30	0.29(0.36-2.32)	0.26
Gfr		
Group 1 (eGFR 60-90)	4.26(1.40-12.88)	0.01
Group 2 (eGFR 30-60)	2.93(0.61-14.11)	0.17
Group 3 (eGFR 29-30)	1	
Group4 (eGFR <15)	1	
DM	1.26(0.48-3.26)	0.64
HTN	1.41 (0.54-3.67)	0.48
Substance Use (any)	3.37(1.15-9.91)	0.03
LDL < 100	Reference	
LDL ≥ 100	0.44(0.16-1.19)	0.11
Heart Failure	2.42(0.92- 6.37)	0.073
CHA₂DS₂-VASc Score ≥ 2	2.33(0.52-10.31)	0.26
Income (As compared to low income)	Reference	
Average Income	1.72(0.48-6.17)	0.40
High Income	7.35 (1.35-40.07)	0.02

5.4 Factors Associated With AF

Patients' sociodemographic and medical characteristics were analyzed to assess their effect on the development of AF. Eleven variables were selected for initial univariate analysis. Of this age category > 65 (COR (95%CI), P value) = 3.41 (1.27-9.18) (0.015), Any substance use, and high-income category were found to have strong evidence of independent association with AF.

In the multivariable analysis, Age, the diagnosis of heart failure, and substance use showed strong evidence of association. Complete results of the multivariable analysis are presented in the (table 4) Accordingly age was the strongest predictor for developing AF (AOR 2.08(1.11-3.89)) ($p=0.02$). We conducted post model estimation tests to assess the fitness of the logistic model. Hosmer Lemishow Test indicates that the specified model fits reasonably well. Additionally, the post model ROC curve indicates that the area under the curve is approximately 0.79 indicates acceptable discrimination for the model.




Figure 3 Post logistic regression ROC Curve

Hence, we can assume the above stated logistic regression model can predict the occurrence of AF reasonably well.

Table 5 Multivariate regression output of selected variables

Variable	AOR	95% CI	P value	AUC
Age	2.08	1.11-3.89	0.02	0.78
Substance Use	2.03	1.04-10.30	0.04	
Heart Failure	3.65	1.27-10.50	0.016	
High Income	12.56	1.97-80.11	0.007	

5.4 Stroke Risk Stratification

Risk stratification was done using CHA2DS2-VASc Score. Accordingly, more than two third of the patients (n= 312, 78.99%) had a score of two or more. All the patients who had already known AF had a CHA2DS2-VASc score greater or equal to two, and 9(81.81%) are on warfarin and the rest of them are on aspirin. However, none of the patients who were newly diagnosed were on anticoagulants. Hence the prevalence of untreated AF among all the participants was 2.53%.




Figure 4 Treatment characteristics in patients with AF

6. Discussion

To the best of our knowledge this is the first systematic non valvular AF screening study in high-risk patients using Single lead ECG recordings in the country. AF was confirmed in 19 patients (4.81%) using the single lead ECG. Out of these A previous diagnosis of Non valvular AF was present in 11 patients (2.78%), and New AF was detected in 8 patients (2.03%).

For a disease to be suitable for screening according to WHO one of the most important criteria is a screening test should be suitable and acceptable to the population⁴⁴. Recent advances in wireless technology have enabled ECG screening for cardiac arrhythmias without the use of 12-lead ECG machines. In our current study we used a wireless smartphone-based device which is a simple, small and portable device, even though 12 lead ECG is the gold standard, it needs a

private room, trained staff and frequent cleaning of the cables especially in the covid era which are luxuries scares in low resource setup like ours.^{45 46}

In our study we found 8 patients (2.03%) with new AF diagnosis which is comparable to the metanalysis of screening studies which found 1.4% new AF in patients above the age of 65⁴⁷. We think this number is underestimated since one time screening can miss cases of paroxysmal AF, as shown in the stroke stop study where AF diagnosis rose from 0.5% from initial electrocardiographic screening to (3.0%; 95% CI, 2.7–3.5) during 2 weeks of twice-daily electrocardiographic recording.⁴³ The overall prevalence of AF was 4.8% in our study which is comparable to a study done in west Ethiopia where 4.3% prevalence of AF was documented.²⁵ It is also comparable to studies done in US AND European populations; a study done from large California health maintenance organization reported an overall prevalence of 5.3% where the prevalence among whites, blacks, Asians, and Hispanics was 8.0%, 3.8%, 3.9%, and 3.6%, respectively⁴⁸ compared to the studies above we have excluded patients with rheumatic heart disease. We have found the positive predictive value of our test to be 86.3% showing it has a low false positive rate compared to other studies which have reported different PPV values ranging from 55%-100%.⁴⁷

Africa is going an epidemiologic shift fueled by urbanization, increased consumption of western diet and lifestyle. According to previous studies, up to two-thirds of cases of AF in Ethiopian patients could be attributed to RHD^{49–51}. We need to challenge this assumption as nonvalvular AF is associated with the afore-mentioned risk factors. Many studies have identified age, male gender, diabetes, hypertension, and heart failure to be risk factors for non-valvular AF. In our study, we have identified age, heart failure, substance use and high-income status, as independent predictors of AF. In our study there was no difference between men and women regarding risk of AF, but male sex has been ascribed as a risk in the Framingham study.⁴¹

Age is one of the strongest predictors of AF in our study with each advancing decade the risk of AF doubles which is similar compared to the Framingham and other epidemiological studies.^{41,52} Cigarette smoking is positively correlated with AF but just short of significance although when it was combined with alcohol use it became a strong predictor of AF.

Other cardiovascular risk factors like hypertension and diabetes were not significantly associated even though they are positively correlated. The reason could be most of our patient population was from diabetic clinic.

Screening a particular disease is justified if there is an adequate and effective treatment once the disease is identified. In the case of AF OAC is an effective way of preventing stroke it can reduce stroke by approximately 60% and death by approximately 25% compared with no antithrombotic treatment⁵³. In our study 9 out of the 11 (2.3%) known AF and none of the New AF patients were on anticoagulation making the prevalence of untreated AF 2.53%. This is a missed opportunity, and the gap needs to be filled by implementing screening procedures equipped with easy-to-use technological advances.



Figure 5 AF by SL ECG Device

7. Recommendations, Conclusion

Single timepoint screening in high-risk patients identified previously unknown AF in 2.1 % of the study population, this is significant because most individuals diagnosed with AF have higher stroke risk. Hence, thrombophylaxis is strongly indicated. Based on the results of this study we argue that targeted screening to detect new AF could contribute to the reduction of stroke and other thromboembolic events. This study has also demonstrated that novel technologies such as Alive core SL device, have simplified the diagnosis of AF and can facilitate implementation of systematic targeted screening in low resource setups.

We recommended screening of atrial fibrillation in selected high-risk patients with simple, easy to use devices like the one used in the study starting from our high-risk clinics. We also recommend this device to be used for larger studies to do population screening so that the true AF prevalence in Ethiopian population can be estimated.

8. Limitation of The Study

The study utilized online tools to collect and ensure quality of data. We also utilized a relatively novel technology of screening AF. However, this study has several limitations, first it was not a large population scale screening and hence generalizability of the results to other settings needs a lot of caution and can be challenging. Second cost effectiveness analysis was not done, third 12 lead ECG was not performed for every study participant designated as sinus rhythm by the SL ECG. Subsequently we were not able to do sensitivity and specificity of the SL device compared to the gold standard even though the device has been validated elsewhere.

9. References

1. Freedman B, Hindricks G, Banerjee A, et al. World Heart Federation roadmap on atrial fibrillation – A 2020 update. *Global Heart*. 2021;16(1). doi:10.5334/GH.1023
2. Bury R, Martin L, Roberts S. Achieving change through mutual development: Supported online learning and the evolving roles of health and information professionals. *Health Information and Libraries Journal*. Published online 2006. doi:10.1111/j.1471-1842.2006.00677.x
3. Gómez-Outes A, Lagunar-Ruiz J, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. *Journal of the American College of Cardiology*. 2016;68(23):2508-2521. doi:10.1016/j.jacc.2016.09.944
4. Hannon N, Sheehan O, Kelly L, et al. Stroke associated with atrial fibrillation--incidence and early outcomes in the north Dublin population stroke study. *Cerebrovascular diseases (Basel, Switzerland)*. 2010;29(1):43-49. doi:10.1159/000255973
5. Flint AC, Banki NM, Ren X, Rao VA, Go AS. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. *Stroke*. 2012;43(10):2788-2790. doi:10.1161/STROKEAHA.112.665844
6. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. *The New England journal of medicine*. 2012;366(2):120-129. doi:10.1056/NEJMoa1105575
7. Herm J, Schurig J, Martinek MR, et al. MRI-detected brain lesions in AF patients without further stroke risk factors undergoing ablation - A retrospective analysis of prospective studies. *BMC Cardiovascular Disorders*. 2019;19(1). doi:10.1186/s12872-019-1035-1
8. Kim D, Yang PS, Yu HT, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: Data from a population-based cohort. *European Heart Journal*. 2019;40(28):2313-2323. doi:10.1093/eurheartj/ehz386
9. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. *European heart journal*. 2013;34(35):2746-2751. doi:10.1093/eurheartj/ehz280
10. Muthalaly RG, Koplán BA, Albano A, et al. Low population prevalence of atrial fibrillation in rural Uganda: A community-based cross-sectional study. *International journal of cardiology*. 2018;271:87-91. doi:10.1016/j.ijcard.2018.05.074
11. Mandi DG, Bamouni J, Naïbé DT, et al. Epidemiology and long-term prognosis of atrial fibrillation in rural African patients. *The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology*. 2019;71(1):6. doi:10.1186/s43044-019-0005-3

12. Freedman B, Hindricks G, Banerjee A, et al. World Heart Federation roadmap on atrial fibrillation – A 2020 update. *Global Heart*. 2021;16(1):1-36. doi:10.5334/GH.1023
13. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *European Heart Journal*. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612
14. Soni A, Karna S, Fahey N, et al. Age-and-sex stratified prevalence of atrial fibrillation in rural Western India: Results of SMART-India, a population-based screening study. *International journal of cardiology*. 2019;280:84-88. doi:10.1016/j.ijcard.2018.12.016
15. Wilson JMG, Jungner G. PRINCIPLES AND PRACTICE OF SCREENING FOR DISEASE.
16. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *Journal of the American College of Cardiology*. 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010
17. Chugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fibrillation in developed and developing nations. *Global heart*. 2014;9(1):113-119. doi:10.1016/j.gheart.2014.01.004
18. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Journal of the American College of Cardiology*. 2014;64(21):e1-76. doi:10.1016/j.jacc.2014.03.022
19. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation*. 2014;129(8):837-847. doi:10.1161/CIRCULATIONAHA.113.005119
20. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. *Journal of the American Heart Association*. 2015;4(1):e001486. doi:10.1161/JAHA.114.001486
21. Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *European heart journal*. 2006;27(8):949-953. doi:10.1093/eurheartj/ehi825
22. Davis RC, Hobbs FDR, Kenkre JE, et al. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. *EP Europace*. 2012;14(11):1553-1559. doi:10.1093/EUROPACE/EUS087
23. Linz D, Sanders P, Pitman B, Dobrev D, Lau DH. Atrial fibrillation in sub-Saharan Africa: The knowns and unknowns? *International journal of cardiology Heart & vasculature*. 2019;22:212-213. doi:10.1016/j.ijcha.2019.02.008
24. Benjamin EJ, Go AS, Desvigne-Nickens P, et al. Research Priorities in Atrial Fibrillation Screening: A Report from a National Heart, Lung, and Blood Institute Virtual Workshop. *Circulation*. Published online 2021:372-388. doi:10.1161/CIRCULATIONAHA.120.047633

25. Tegene E, Tadesse I, Markos Y, Gobena T. Prevalence and risk factors for atrial fibrillation and its anticoagulant requirement in adults aged ≥ 40 in Jimma Town, Southwest Ethiopia: A community based cross-sectional study. *IJC Heart and Vasculature*. 2019;22:199-204. doi:10.1016/j.ijcha.2019.02.003
26. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. *Stroke*. 1996;27(10):1760-1764. doi:10.1161/01.str.27.10.1760
27. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation*. 2004;110(9):1042-1046. doi:10.1161/01.CIR.0000140263.20897.42
28. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Annals of internal medicine*. 2007;146(12):857-867. doi:10.7326/0003-4819-146-12-200706190-00007
29. Hobbs FDR, Fitzmaurice DA, Mant J, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. *Health Technology Assessment*. 2005;9(40). doi:10.3310/hta9400
30. Recommendations | Atrial fibrillation: diagnosis and management | Guidance | NICE.
31. Jones NR, Taylor CJ, Hobbs FDR, Bowman L, Casadei B. Screening for atrial fibrillation: a call for evidence. *European Heart Journal*. 2020;41(10):1075-1085. doi:10.1093/eurheartj/ehz834
32. Jonas DE, Kahwati LC, Yun JDY, Cook Middleton J, Coker-Schwimmer M, Asher GN. Screening for atrial fibrillation with electrocardiography: Evidence report and systematic review for the US preventive services task force. *JAMA - Journal of the American Medical Association*. 2018;320(5):485-498. doi:10.1001/jama.2018.4190
33. Mant J, Fitzmaurice DA, Hobbs FDR, et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. *BMJ (Clinical research ed)*. 2007;335(7616):380. doi:10.1136/bmj.39227.551713.AE
34. Jones NR, Taylor CJ, Hobbs FDR, Bowman L, Casadei B. Screening for atrial fibrillation: A call for evidence. *European Heart Journal*. 2020;41(10):1075-1085. doi:10.1093/eurheartj/ehz834
35. Pitman BM, Chew SH, Wong CX, et al. Performance of a mobile single-lead electrocardiogram technology for atrial fibrillation screening in a semirural African population: Insights from "The heart of Ethiopia: Focus on atrial fibrillation" (TEFF-AF) study. *JMIR mHealth and uHealth*. 2021;9(5):1-10. doi:10.2196/24470
36. Lowres N, Neubeck L, Redfern J, Ben Freedman S. Screening to identify unknown atrial fibrillation: A systematic review. *Thrombosis and Haemostasis*. 2013;110(2):213-222. doi:10.1160/TH13-02-0165

37. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation the STROKESTOP study. *Circulation*. 2015;131(25):2176-2184. doi:10.1161/CIRCULATIONAHA.114.014343
38. Khurshid S, Healey JS, McIntyre WF, Lubitz SA. Population-Based Screening for Atrial Fibrillation. *Circulation Research*. Published online 2020:143-154. doi:10.1161/CIRCRESAHA.120.316341
39. Benjamin EJ, Go AS, Desvigne-Nickens P, et al. Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. *Circulation*. 2021;143(4):372-388. doi:10.1161/CIRCULATIONAHA.120.047633
40. Hofman A, Breteler MMB, van Duijn CM, et al. The Rotterdam Study: objectives and design update. *European journal of epidemiology*. 2007;22(11):819-829. doi:10.1007/S10654-007-9199-X
41. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study - PubMed. Accessed December 4, 2021. <https://pubmed.ncbi.nlm.nih.gov/8114238/>
42. WHO STEPS Instrument (Core and Expanded) STEPS Instrument Overview. Accessed December 8, 2021. www.who.int/chp/steps
43. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation the STROKESTOP study. *Circulation*. 2015;131(25):2176-2184. doi:10.1161/CIRCULATIONAHA.114.014343
44. Wilson JMG, Jungner G. *PRINCIPLES AND PRACTICE OF SCREENING FOR DISEASE*.
45. Evans GF, Shirk A, Muturi P, Soliman EZ. Feasibility of Using Mobile ECG Recording Technology to Detect Atrial Fibrillation in Low-Resource Settings. *Global Heart*. 2017;12(4):285-289. doi:10.1016/j.gheart.2016.12.003
46. Azram M, Ahmed N, Leese L, et al. Clinical validation and evaluation of a novel six-lead handheld electrocardiogram recorder compared to the 12-lead electrocardiogram in unselected cardiology patients (EVALECG Cardio). *European Heart Journal - Digital Health*. Published online September 28, 2021. doi:10.1093/EHJDH/ZTAB083
47. Lowres N, Neubeck L, Redfern J, ben Freedman S. Screening to identify unknown atrial fibrillation: A systematic review. *Thrombosis and Haemostasis*. 2013;110(2):213-222. doi:10.1160/TH13-02-0165
48. Shen AYJ, Contreras R, Sobnosky S, et al. Racial/Ethnic Differences in the Prevalence of Atrial Fibrillation Among Older Adults—A Cross-Sectional Study. *Journal of the National Medical Association*. 2010;102(10):906-914. doi:10.1016/S0027-9684(15)30709-4
49. Zewudie AZ, Regasa T, Hambisa S, et al. Treatment Outcome and Its Determinants among Patients Admitted to Stroke Unit of Jimma University Medical Center, Southwest Ethiopia. *Stroke research and treatment*. 2020;2020:8817948. doi:10.1155/2020/8817948
50. Characteristics and outcomes of stroke at Tikur Anbessa Teaching Hospital, Ethiopia - PubMed. Accessed December 3, 2021. <https://pubmed.ncbi.nlm.nih.gov/16523645/>

51. View of Prevalence and Predictors of Atrial Fibrillation and its Embolic Complications in Patients with Rheumatic Heart Disease at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. Accessed December 3, 2021.
<http://ejol.ethernet.edu.et/index.php/EJHD/article/view/1265/1010>
52. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 1. *American Journal of Cardiology*. 1998;82(7):2N-9N. doi:10.1016/S0002-9149(98)00583-9
53. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Annals of internal medicine*. 2007;146(12):857-867. doi:10.7326/0003-4819-146-12-200706190-00007